G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Get Alerts GTHX Hot Sheet
Join SI Premium – FREE
RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference. The fireside chat will take place on June 22nd at 9:20 AM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contacts:Will RobertsVice President, Investor Relations & Corporate Communications919-907-1944 [email protected]
Source: G1 TherapeuticsSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Sharecare, Inc. (SHCR)
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Palo Alto, Snowflake, and Chemours and Encourages Investors to Contact the Firm
- Ridgeline Minerals Announces Upsized Non-Brokered Private Placement to $2.2M
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Raymond James, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!